What is the Shilpa Medicare PE ratio today?
Shilpa Medicare's PE ratio is 61.5 at the 29 October 2026 close (₹935.60 a share): a market capitalisation of ₹18,291 crore divided by consolidated net profit of ₹297 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹243 crore) it is 75.2.
What is the Shilpa Medicare debt to equity ratio?
Shilpa Medicare's debt-to-equity ratio was 0.25 on 31 March 2026: borrowings of ₹658 crore against total equity of ₹2,591 crore. A year earlier, on 31 March 2025, it was 0.25.
What is the Shilpa Medicare net worth?
Shilpa Medicare's net worth — shareholders' equity in its consolidated balance sheet — was ₹2,591 crore on 31 March 2026, up 9.2% from ₹2,372 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹18,291 crore at the 29 October 2026 close.
What is the Shilpa Medicare PB ratio (price to book value)?
Shilpa Medicare's price-to-book (PB) ratio is 7.06 at the 29 October 2026 close: a market capitalisation of ₹18,291 crore divided by shareholders' equity (book value) of ₹2,591 crore on 31 March 2026. That is a book value of ₹132.54 per share against a share price of ₹935.60.
What is the Shilpa Medicare ROE and ROCE?
In FY26, Shilpa Medicare's return on equity (ROE) was 9.8% and its return on capital employed (ROCE) was 11.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 3.8% and ROCE 8.1%.
What is the Shilpa Medicare shareholding pattern?
On 30 September 2026, Shilpa Medicare's shares were held by promoters 40.13%, foreign portfolio investors (FII/FPI) 12.11%, domestic institutions (DII) 8.26% (including mutual funds at 4.20%) and retail and other non-institutional investors 39.49%. Over the year, FII holding was up 1.19 percentage points from 10.92% and DII holding was up 0.59 percentage points from 7.67%.
What is the Shilpa Medicare market cap?
Shilpa Medicare's market capitalisation was ₹18,291 crore at the 29 October 2026 close: 19.55 crore shares at ₹935.60 each.
Is Shilpa Medicare debt free?
No. Shilpa Medicare had borrowings of ₹658 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.25. Its cash and current investments were ₹45.2 crore, so its net debt was ₹613 crore.
What is the Shilpa Medicare dividend in 2026 and its record date?
In 2026, Shilpa Medicare has declared one dividend: ₹0.60 with record date 4 September 2026.
What is the Shilpa Medicare book value per share?
Shilpa Medicare's book value per share was ₹132.54 on 31 March 2026: shareholders' equity of ₹2,591 crore divided by the 19.55 crore shares in issue. The share price at the 29 October 2026 close was ₹935.60.
What is the Shilpa Medicare free cash flow?
In FY26, Shilpa Medicare generated ₹342 crore of cash from operations and spent ₹371 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹28.5 crore. In FY25 it was −₹111 crore.
What is the Shilpa Medicare revenue and profit in FY26?
In FY26 (April 2025–March 2026), Shilpa Medicare's consolidated net profit was ₹243 crore, up 210.8% from ₹78.3 crore in FY25, on revenue from operations of ₹1,539 crore (up 19.6%).
What is the Shilpa Medicare EPS?
Shilpa Medicare's basic earnings per share (EPS) were ₹12.44 in FY26.
What is the Shilpa Medicare promoter holding?
Promoters held 40.13% of Shilpa Medicare on 30 September 2026, unchanged from the previous quarter and down 4.10 percentage points from 44.23% a year earlier, according to the shareholding pattern filed with NSE.
When are the Shilpa Medicare next results?
Shilpa Medicare will announce its Q2 FY27 results (July–September 2026) on Thursday, 5 November 2026, the date of the board meeting it has notified to the exchanges.
What are the Shilpa Medicare latest quarterly results?
Shilpa Medicare's latest results are for Q1 FY27 (April–June 2026), filed on 5 August 2026: consolidated net profit ₹101 crore, up 115.2% from ₹46.9 crore in Q1 FY26; revenue from operations ₹466 crore, up 44.9% year on year.
How does the Shilpa Medicare PE ratio compare with its peers?
At the 29 October 2026 closing prices, on FY26 net profit, Shilpa Medicare's PE ratio is 75.2, the highest of the four: NATCO Pharma 9.9, Sun Pharma Advanced Research 3.8 and Strides Pharma Science 18.2, a peer average of 10.6. Each is the company's market capitalisation at that price divided by its FY26 net profit.
Shilpa Medicare vs NATCO Pharma: how do they compare?
In FY26, Shilpa Medicare earned net profit of ₹243 crore on revenue of ₹1,539 crore, against ₹1,419 crore on ₹4,078 crore for NATCO Pharma. Shilpa Medicare's operating margin was 20.5% (NATCO Pharma 30.2%) and its return on equity 9.8% (NATCO Pharma 16.9%). At the 29 October 2026 close, Shilpa Medicare's market capitalisation was ₹18,291 crore against ₹14,097 crore for NATCO Pharma, and its PE ratio on FY26 profit 75.2 against 9.9.
How does Shilpa Medicare compare with its peers?
On FY26 consolidated figures, against NATCO Pharma, Sun Pharma Advanced Research and Strides Pharma Science: Shilpa Medicare's operating margin of 20.5% is the third highest of the four (NATCO Pharma 30.2%, Sun Pharma Advanced Research 84.5%, Strides Pharma Science 14.9%; peer average 43.2%); its return on equity of 9.8% is the lowest of the four (NATCO Pharma 16.9%, Sun Pharma Advanced Research 277.4%, Strides Pharma Science 19.7%; peer average 104.6%); its revenue growth over three years of 13.6% a year is the third highest of the four (NATCO Pharma 14.6% a year, Sun Pharma Advanced Research 96.0% a year, Strides Pharma Science 9.6% a year; peer average 40.1% a year).
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
